Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update

MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update MoonLake Immunotherapeutics (NASDAQ:MLTX) is placed eighth on our list of most promising stocks. TheFly reported on February 26 that Goldman Sachs increased its price target on MLTX to $11 from $10 and maintained a Sell rating. The update followed the company’s fourth-quarter an ...